Previous 10 | Next 10 |
Arcturus Therapeutics press release (NASDAQ:ARCT): Q1 GAAP EPS of -$1.94 misses by $0.63. Revenue of $5.24M (+146.0% Y/Y) misses by $1.84M. For further details see: Arcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84M
ARCT-154 booster data show 54- and 46-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARC...
Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$1.40 (+34.9% Y/Y) and the consensus Revenue Estimate is $7.08M (+232.4% Y/Y). Over the last 3 months, EPS estimates have seen 5 upward revis...
Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Please replace the graphic with the accompanying cor...
Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO Arcturus Therapeutics Holdings Inc. (the “Com...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory ra...
Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months. Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback...
Earnings news provided a crucial catalyst during Thursday's midday trading. American Airlines (NASDAQ:AAL) ranked among the standout performers, rising in the wake of its upbeat results. Meanwhile, Watsco (WSO) and Steel Dynamics (STLD) both rose after their respective quarterly updates. Look...
Gainers: Inozyme Pharma (INZY) +15%. Clarus Therapeutics (CRXT) +10%. MedAvail (MDVL) +5%. Syros Pharmaceuticals (SYRS) +5%. Magenta Therapeutics (MGTA) +4%. Losers: AlloVir (ALVR) -10%. Rite Aid (RAD) -9%. Windtree Therapeutics (WINT) -7...
Arcturus Therapeutics (NASDAQ:ARCT) was downgraded to Neutral at Citi with a price target of $29, down from $86, as the firm noted that the path forward for the company's mRNA vaccine ARCT-154 was 'too risky.' On April 20, the company reported data from an ongoing phase 1/2/3 trial ...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...